Effect of caffeine on clozapine pharmacokinetics in healthy volunteers
Hägg S, Spigset O, Mjörndal T, Dahlqvist R
British journal of clinical pharmacology · 45 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2000-01-01 · Br J Clin Pharmacol · vol. 49 · número 1 · págs. 59–63
- Editorial
- Wiley
- Citado
- 78 citas · más que el 87% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 19 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Pharmacogenetics and Drug Metabolism · Coffee research and impacts · Schizophrenia research and treatment
- Palabras clave
- caffeine, clozapine, pharmacokinetics, drug-drug interactions, clozapine-N-oxide, paraxanthine, caffeine metabolism, oral clearance, healthy volunteers
- MeSH
- humans, caffeine, theophylline, clozapine, antipsychotic agents, central nervous system stimulants, chromatography, high pressure liquid, area under curve, cross-over studies, biotransformation, adult, male
4 autores
- Staffan Hägg🇸🇪 · autor de correspondenciaUniversity Hospital of Umeå
- Olav Spigset🇸🇪University Hospital of Umeå
- Tom Mjörndal🇸🇪University Hospital of Umeå
- Rune Dahlqvist🇸🇪University Hospital of Umeå
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aims
To assess the effects of caffeine on the pharmacokinetics of clozapine in healthy volunteers.
Methods
This was an open label randomized crossover study in 12 nonsmoking healthy male volunteers. The subjects received a single oral dose of 12.5 mg clozapine in each phase with or without concomitant intake of caffeine (mean dose: 550 mg day-1, range: 400-1000 mg day-1 ). Serum concentrations of clozapine and its metabolites desmethyl-clozapine and clozapine-N-oxide were measured during a 48 h period in each phase. In addition, serum concentrations of caffeine and the metabolite paraxanthine were monitored.
Results
A 19% increase in mean clozapine AUC(0,infinity) (P=0.05) and a 14% decrease of mean oral clearance of clozapine were observed during concomitant intake of caffeine (P=0.05) compared with intake of only clozapine. Statistically significant decreases of mean ratios between AUC(0, 12h) for desmethyl-clozapine and AUC(0,12h) for clozapine (-18%), and between AUC(0,12h) for clozapine-N-oxide and AUC(0,12h) for clozapine (-23%) were observed during the caffeine phase (P=0.03 and 0.02, respectively). Oral clearance of clozapine and the ratio AUC(0, 12h) for desmethyl-clozapine/AUC(0,12h) for clozapine were correlated with the paraxanthine/caffeine ratio in serum after intake of caffeine (rs=0.62; P=0.03 and rs=0.77; P=0.003, respectively).
Conclusions
These results suggest that caffeine in daily doses of 400-1000 mg inhibits the metabolism of clozapine to an extent that might be clinically significant in certain individuals.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.